-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Advanced Neurovascular Access (ANA) Thrombectomy System is a novel stroke thrombectomy device that includes a self-expanding funnel designed to reduce thrombus fragmentation by locally restricting blood flow while becoming as wide as the artery in which it resides
.
Once deployed, the ANA device allows distal aspiration, which, in combination with the stent retriever, mobilizes the thrombus into the funnel, where it remains trapped during aspiration
The Advanced Neurovascular Access (ANA) Thrombectomy System is a novel stroke thrombectomy device that includes a self-expanding funnel designed to reduce thrombus fragmentation by locally restricting blood flow while becoming as wide as the artery in which it resides
The study included all eligible patients with anterior circulation vessel occlusion who were admitted to the hospital within 8 hours of stroke symptom onset
.
The primary endpoint was successful reperfusion using the ANA device in combination with the stent retriever (Modified Thrombolysis Score 2b-3 in Cerebral Infarction) in the intention-to-treat population prior to the use of salvage therapy
After enrolling 74 patients, an interim analysis was conducted, and the trial steering committee decided to discontinue enrollment due to meeting safety and performance goals
.
The mean age was 71.
After enrolling 74 patients, an interim analysis was conducted, and the trial steering committee decided to discontinue enrollment due to meeting safety and performance goals
60/72 patients successfully achieved reperfusion (83.
After 90 days, draw the mRS score ending
After 90 days, draw the mRS score endingOverall, the first successful recanalization rate was 55.
6% (95% CI, 44.
1%-67.
0%) and the first complete recanalization rate was 38.
9% (95% CI, 27.
6%-50.
1%)
.
Twelve of 72 (17%) patients required salvage therapy to obtain a modified Thrombolysis Score for cerebral infarction 2b-3
After 90 days, the rate of good functional outcome (mRS 0-2) was 57.
In this clinical experience, the ANA device achieved a high rate of complete recanalization with a preliminary favorable safety profile and favorable 90-day clinical outcomes
references:
references:Clinical Results of the Advanced Neurovascular Access Catheter System Combined With a Stent Retriever in Acute Ischemic Stroke (SOLONDA).
Clinical Results of the Advanced Neurovascular Access Catheter System Combined With a Stent Retriever in Acute Ischemic Stroke (SOLONDA).
Stroke.
2022;0:10.
1161/STROKEAHA.
121.
037577.
Leave a comment here